TABLE 3.
Management and clinical outcome of non-AML myeloid neoplasm patients with NPM1 mutations.
| Management, follow-up and survival | |
|---|---|
| Treatment | Supportive treatment: 29% (10/34) Other therapy: 65% (22/34) • Hypomethylating agent: 55% • Chemotherapy: 7% • BM transplant: 24% Lost to follow-up: 6% (2/34) |
| Transformation to AML or increase in blasts | 9 patients transformed to AML • 6MDS-EB • 2 MDS-EB1 4 MDS-EB2 • 1CMML-2 • 1 MDS-MLD • 1 MDS/MPN-U 1 patient had an increase in blasts (<20%) • MDS(RCMD) |
| AML relapsea | Positive: 78% (7/9) Negative: 11% (1/9) Not known: 11% (1/9) |
| Follow-up | 29.5 months (median); 41.7 months (mean) |
| Survival | Total median OS(n = 34): 70 months OS in patients with progression to AML (n = 9): 20 monthsb OS in patients without progression to AML (n = 25): 128 monthsb |
a
Patients who progressed to AML and received appropriate treatment had disease relapse after initial response. Most patients received chemotherapy treatment.
b
log rank p = 0.05.